Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adults
NCT06326671Phase 1Active, not recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Feb 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tiotropium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Peak Concentration at 216 hours, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration and 1 more. Started Feb 2024; status: active, not recruiting.
02
Drugs
tiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06326671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326671.